NNC0165-1875
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Novo Nordisk · Phase 2 · Completed · Enrollment 120
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg and NNC0165-1875 2.0 mg | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg) | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg and NNC0165-1875 1.0 mg | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg) | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.